Oslo - Delayed Quote
NOK
Oncoinvent ASA (ONCIN.OL)
65.40
-3.60
(-5.22%)
At close: 4:25:12 PM GMT+1
Key Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Oystein Soug M.Sc
|
Chief Executive Officer | 4.59M | -- | 1969 |
|
Ms. Gro Elisabeth Hjellum
|
Chief Operating Officer | 2.82M | -- | -- |
|
Ms. Kristine Lofthus
|
Chief Production Officer | 2.1M | -- | -- |
Oncoinvent ASA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 42
Description
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
Corporate Governance
Oncoinvent ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 27, 2026 at 2:20 PM UTC
Oncoinvent ASA Earnings Date
Recent Events
Recent Events Information Not Available
